FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072940754> ?p ?o ?g. }

• W2072940754 endingPage "1762" @default.
• W2072940754 startingPage "1754" @default.
• W2072940754 abstract "Abstract To assess the value of administering timed-sequential chemotherapy (TSC; 2 therapeutic sequences separated by a 4-day interval-free chemotherapy) or high-dose cytarabine (HDAraC) cycles in consolidation therapy for acute myeloid leukemia (AML), 459 patients 15 to 50 years of age were enrolled in the prospective randomized Acute Leukemia French Association–9802 trial. Complete remission was achieved in 89%. A total of 237 patients were then randomized to either TSC consolidation (120 patients) or HDAraC consolidation cycles (117 patients). Overall, there was no significant difference between the 2 consolidation arms (5-year event-free survival [EFS]: 41% for HDAraC vs 35% for TSC), or cumulative incidence of relapse, or treatment-related mortality. Cytogenetically normal AML NPM1+ or CEBPA+ and FLT3-ITD− had the same outcome as those with favorable cytogenetics. When considering favorable and unfavorable risk groups, the trend was in favor of HDAraC. However, the difference became significant when considering intermediate cytogenetics (5-year EFS: 49% vs 29%; P = .02), especially cytogenetically normal AML (5-year EFS: 48% vs 31%; P = .04), which was related to lower relapse rate and less toxicity. This study demonstrates that TSC did not produce any benefit when used as consolidation therapy in younger adults compared with HDAraC. This trial was registered at www.clinicaltrials.gov as #NCT00880243." @default.
• W2072940754 created "2016-06-24" @default.
• W2072940754 creator A5000000264 @default.
• W2072940754 creator A5000436961 @default.
• W2072940754 creator A5010517016 @default.
• W2072940754 creator A5014838075 @default.
• W2072940754 creator A5017435311 @default.
• W2072940754 creator A5018416096 @default.
• W2072940754 creator A5022341207 @default.
• W2072940754 creator A5028365885 @default.
• W2072940754 creator A5028508696 @default.
• W2072940754 creator A5046391226 @default.
• W2072940754 creator A5048132509 @default.
• W2072940754 creator A5050799774 @default.
• W2072940754 creator A5052966035 @default.
• W2072940754 creator A5054745373 @default.
• W2072940754 creator A5058825074 @default.
• W2072940754 creator A5064103067 @default.
• W2072940754 creator A5067465993 @default.
• W2072940754 creator A5072027146 @default.
• W2072940754 creator A5072721892 @default.
• W2072940754 creator A5076973611 @default.
• W2072940754 date "2011-08-18" @default.
• W2072940754 modified "2023-10-01" @default.
• W2072940754 title "Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study" @default.
• W2072940754 cites W1492445977 @default.
• W2072940754 cites W1492609361 @default.
• W2072940754 cites W1534965621 @default.
• W2072940754 cites W1930980342 @default.
• W2072940754 cites W1969545468 @default.
• W2072940754 cites W1990870968 @default.
• W2072940754 cites W2000580405 @default.
• W2072940754 cites W2016231313 @default.
• W2072940754 cites W2026241511 @default.
• W2072940754 cites W2034506866 @default.
• W2072940754 cites W2035953198 @default.
• W2072940754 cites W2043216151 @default.
• W2072940754 cites W2043938406 @default.
• W2072940754 cites W2052752328 @default.
• W2072940754 cites W2053487253 @default.
• W2072940754 cites W2074425311 @default.
• W2072940754 cites W2098854099 @default.
• W2072940754 cites W2101740056 @default.
• W2072940754 cites W2105573850 @default.
• W2072940754 cites W2118693086 @default.
• W2072940754 cites W2120440386 @default.
• W2072940754 cites W2123081362 @default.
• W2072940754 cites W2143815043 @default.
• W2072940754 cites W2147213204 @default.
• W2072940754 cites W2150113701 @default.
• W2072940754 cites W2155349260 @default.
• W2072940754 cites W2158862325 @default.
• W2072940754 cites W2158872718 @default.
• W2072940754 cites W2159507916 @default.
• W2072940754 cites W2163112291 @default.
• W2072940754 cites W2170846829 @default.
• W2072940754 cites W2318674152 @default.
• W2072940754 cites W4376595466 @default.
• W2072940754 doi "https://doi.org/10.1182/blood-2011-04-349258" @default.
• W2072940754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21690555" @default.
• W2072940754 hasPublicationYear "2011" @default.
• W2072940754 type Work @default.
• W2072940754 sameAs 2072940754 @default.
• W2072940754 citedByCount "48" @default.
• W2072940754 countsByYear W20729407542012 @default.
• W2072940754 countsByYear W20729407542013 @default.
• W2072940754 countsByYear W20729407542014 @default.
• W2072940754 countsByYear W20729407542015 @default.
• W2072940754 countsByYear W20729407542016 @default.
• W2072940754 countsByYear W20729407542017 @default.
• W2072940754 countsByYear W20729407542018 @default.
• W2072940754 countsByYear W20729407542019 @default.
• W2072940754 countsByYear W20729407542020 @default.
• W2072940754 countsByYear W20729407542021 @default.
• W2072940754 countsByYear W20729407542022 @default.
• W2072940754 countsByYear W20729407542023 @default.
• W2072940754 crossrefType "journal-article" @default.
• W2072940754 hasAuthorship W2072940754A5000000264 @default.
• W2072940754 hasAuthorship W2072940754A5000436961 @default.
• W2072940754 hasAuthorship W2072940754A5010517016 @default.
• W2072940754 hasAuthorship W2072940754A5014838075 @default.
• W2072940754 hasAuthorship W2072940754A5017435311 @default.
• W2072940754 hasAuthorship W2072940754A5018416096 @default.
• W2072940754 hasAuthorship W2072940754A5022341207 @default.
• W2072940754 hasAuthorship W2072940754A5028365885 @default.
• W2072940754 hasAuthorship W2072940754A5028508696 @default.
• W2072940754 hasAuthorship W2072940754A5046391226 @default.
• W2072940754 hasAuthorship W2072940754A5048132509 @default.
• W2072940754 hasAuthorship W2072940754A5050799774 @default.
• W2072940754 hasAuthorship W2072940754A5052966035 @default.
• W2072940754 hasAuthorship W2072940754A5054745373 @default.
• W2072940754 hasAuthorship W2072940754A5058825074 @default.
• W2072940754 hasAuthorship W2072940754A5064103067 @default.
• W2072940754 hasAuthorship W2072940754A5067465993 @default.
• W2072940754 hasAuthorship W2072940754A5072027146 @default.
• W2072940754 hasAuthorship W2072940754A5072721892 @default.
• W2072940754 hasAuthorship W2072940754A5076973611 @default.
• W2072940754 hasBestOaLocation W20729407541 @default.

• next